Deep Track Capital

Imbria Pharmaceuticals, founded in 2018 and headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies targeting cardiometabolic disorders. The company focuses on understanding the underlying mechanisms of these diseases, particularly energetic impairment at the cellular level, to inform its therapeutic candidates. Imbria's pipeline aims to improve the lives of patients suffering from conditions such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction by restoring or enhancing cellular energy production.

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.

Tectonic Therapeutic is a biotechnology company dedicated to the discovery and development of innovative drugs that target G protein-coupled receptors (GPCRs). With a focus on therapeutic proteins and antibodies, Tectonic aims to address the complexities of GPCR-targeted drug discovery through its proprietary technology platform, GEODe. The company is committed to unlocking the therapeutic potential of challenging receptors, striving to create biologic medicines that can effectively modify disease progression. Founded by experts in biochemistry and molecular pharmacology, Tectonic combines a strong scientific foundation with a history of entrepreneurial success to advance its mission in the biopharmaceutical landscape.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It is dedicated to discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. The company employs a proprietary discovery and development engine to create highly selective small molecules that modulate immune responses related to these conditions. RAPT has advanced two notable drug candidates: FLX475, which targets the inhibition of immunosuppressive regulatory T cells in tumors, and RPT193, which selectively inhibits type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short timeframe since the company's inception. Additionally, RAPT is exploring several other targets in the discovery phase, including general control nonderepressible 2 and hematopoietic progenitor kinase 1.

Maze Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, established in 2017. The company specializes in developing genetic modifier therapeutics aimed at addressing unmet medical needs. Utilizing its innovative Compass platform, Maze Therapeutics focuses on identifying rare genetic variants that offer protective effects against diseases. By analyzing large-scale human genetic data and employing functional genomics, the company maps these variants to the biological pathways that contribute to specific conditions in patient populations. This approach enables a deeper understanding of target biology and facilitates the development of novel therapies, positioning Maze Therapeutics as a key player in translating genetic insights into effective medicines.

35Pharma is a biopharmaceutical company focused on designing and developing innovative biologics to address diseases with high unmet medical needs, particularly pulmonary hypertension and musculoskeletal disorders. The company leverages its expertise in protein engineering and its understanding of transforming growth factor-beta (TGF-beta) structure-function relationships to create highly potent ligand traps. These developments aim to enhance treatment options for patients suffering from cardio-pulmonary and metabolic diseases. By combining advanced scientific knowledge with a commitment to addressing critical health challenges, 35Pharma seeks to contribute significantly to the biopharmaceutical landscape.

enGene, Inc. is a biotechnology company based in Vancouver, Canada, specializing in mucosal immunotherapy to address inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables the localized delivery of immune-modulating proteins to mucosal tissues, targeting conditions affecting the gastrointestinal tract, lung, and bladder. This innovative platform allows for the systemic release of proteins from the gut, which can be beneficial for treating a variety of immune disorders, as well as other conditions such as diabetes, anemia, and hemophilia. Founded in 1999, enGene has formed a strategic alliance with Takeda Pharmaceutical Company to further advance its therapeutic offerings.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

OnKure Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of innovative cancer therapies. The company specializes in creating less toxic kinase inhibitor drugs and epigenetic therapies, including selective inhibitors of histone deacetylases. Its lead candidate, OKI-179, has demonstrated significant efficacy in preclinical models of hematological and solid tumor cancers, effectively reducing tumor growth both alone and in combination with other targeted therapies. Additionally, OnKure is advancing its HDAC3 selective inhibitor, OKI-422, into preclinical toxicology studies. The company's drug candidates are designed to directly target malignant cells, enhance the effects of small molecule therapies, and optimize the tumor microenvironment for improved checkpoint inhibition, addressing unmet medical needs in cancer treatment.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

Halda Therapeutics is a research-stage drug discovery company dedicated to developing next-generation precision medicine. The company employs a unique therapeutic modality that serves as a platform for addressing various disease states. By focusing on the discovery of novel therapies that modify disease-causing pathways, Halda Therapeutics aims to enable healthcare providers to offer more targeted treatments for their patients. Through its innovative approach, the company seeks to advance the field of precision medicine and improve patient outcomes.

MBX Biosciences, Inc. is a biotechnology company founded in 2018 and based in Carmel, Indiana. The company specializes in developing therapeutics for rare endocrine disorders, focusing on conditions that currently lack effective treatments. MBX Biosciences aims to discover, develop, and commercialize first-in-class therapies, particularly peptides designed to address endocrine genetic diseases that affect glandular hormone production and the body’s chemical messaging systems.

Jade Biosciences is a biopharmaceutical company dedicated to developing innovative therapies for unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the APRIL pathway for treating IgA nephropathy, with initial clinical trials planned. Additionally, Jade has two preclinical antibody discovery programs, JADE-002 and JADE-003. The company was founded upon assets licensed from Paragon Therapeutics.

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of a novel class of medicines known as Bicycles. These are synthetic short peptides designed to form two loops that stabilize their structure. The company's lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) currently undergoing Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also a BTC in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies targeting Nectin-4. Additionally, Bicycle is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to address therapeutic areas such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics was incorporated in 2009 and aims to address significant unmet medical needs in oncology and beyond.

Context Therapeutics LLC is a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, focused on developing innovative therapies for hormone-responsive cancers. Founded in 2015, the company is dedicated to creating new medicines primarily for female cancers, including breast, ovarian, and endometrial cancer. Its lead program, Apristor (Onapristone XR), is an investigational Phase 2 drug targeting progesterone receptor positive metastatic breast and ovarian cancers. In addition to Apristor, Context is advancing CTX-030916, a potential oral antiprogestin for treating uterine fibroids and endometriosis. The company is also developing a preclinical program, CTIM-76, which is a bispecific antibody designed to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. Through its innovative pipeline, Context Therapeutics aims to address unmet medical needs in the treatment of solid tumors.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Zura Bio is a clinical-stage biotechnology company dedicated to developing innovative therapies for immune and inflammatory disorders. It focuses on advancing its pipeline of treatments through phase 2 development programs, including ZB-168 and torudokimab, which target autoimmune illnesses. ZB-168 is an anti-IL7R inhibitor designed to address disorders linked to IL7 and TSLP biological pathways, building on encouraging phase 1b data related to type 1 diabetes. Torudokimab, a human-affinity monoclonal antibody, is in phase 2 clinical development and works by neutralizing IL33. Through these initiatives, Zura Bio aims to create effective therapeutic options for patients suffering from complex immune-related conditions.

Inovio Pharmaceuticals, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of DNA medicines aimed at treating, curing, and protecting individuals from diseases related to human papillomavirus (HPV), cancer, and infectious diseases. The company's innovative SynCon immunotherapy design enables the immune system to target cancerous cells while providing cross-strain protection against various pathogens. Inovio's clinical studies focus on HPV-associated precancers, cancers, and other disorders, as well as diseases such as glioblastoma multiforme, HIV, and COVID-19. The company has developed a proprietary delivery system that allows DNA medicine to be introduced directly into cells, producing a strong immune response. Notably, its lead candidate, VGX-3100, is undergoing Phase 3 trials for precancerous cervical dysplasia, having shown promise in earlier trials by effectively clearing high-risk HPV strains. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio collaborates with various partners, including major pharmaceutical companies and research institutions, to advance its clinical initiatives and expand its therapeutic reach.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, that specializes in developing therapeutic drugs for hyperexcitability disorders affecting the nervous system. Founded in 2018, the company focuses on creating innovative treatments for conditions such as chronic pain, depression, epilepsy, and anxiety, which significantly impact millions of individuals. Eliem utilizes its expertise in neuroscience and translational medicine to advance a promising pipeline of drug candidates, including its lead candidate, ETX-155, aimed at addressing major depressive disorder and focal onset seizures. The company's mission centers on meeting unmet medical needs and improving patients' quality of life through its novel therapies.

TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, antibody-based therapies aimed at enhancing the lives of cancer patients. The company specializes in antibody-drug conjugates and other biologics, focusing on oncologic diseases with significant unmet medical needs. TORL BioTherapeutics employs a strategy that involves target identification and early discovery work, allowing them to selectively advance drug programs through novel licensing agreements. This approach enables their researchers to develop proprietary drugs with unique and optimized profiles, contributing to the advancement of cancer treatment options.

Avalo Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing highly targeted therapeutics for immune dysregulation and other areas of significant unmet clinical need. The company employs a precision medicine approach in its research and development efforts. Its lead asset, AVTX-009, is an anti-IL-1B monoclonal antibody designed to address inflammatory diseases. In addition to AVTX-009, Avalo's pipeline includes quisovalimab, an anti-LIGHT monoclonal antibody, and AVTX-008, a BTLA agonist fusion protein, which further exemplify its commitment to advancing innovative treatments for complex medical conditions.

Avenzo Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for oncology, specifically targeting underserved and rare cancers. The company operates a specialized platform that focuses on creating novel treatments aimed at genomically defined cancer types. By prioritizing targeted therapies, Avenzo Therapeutics seeks to advance cancer treatment options for patients who may not have access to effective solutions, thus addressing significant gaps in the current therapeutic landscape.

Geron Corporation is a late-stage clinical biopharmaceutical company based in Menlo Park, California, specializing in the development and commercialization of therapeutics for hematologic malignancies. Established in 1990, the company is primarily focused on its investigational drug, imetelstat, a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. Imetelstat targets the uncontrolled proliferation of malignant progenitor cells, aiming to improve blood cell production in patients with conditions such as myelodysplastic syndromes and myelofibrosis. Geron generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements, positioning itself as a key player in oncology therapeutics.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies aimed at transforming the treatment landscape for inflammatory bowel disease (IBD). By leveraging advanced antibody engineering, rational therapeutic combinations, and precision medicine strategies for patient selection, Spyre Therapeutics seeks to create next-generation products that address the chronic inflammation associated with IBD, which includes ulcerative colitis and Crohn's disease. The company aims to enhance existing treatment options, which currently include anti-inflammatory drugs, immunosuppressants, and biologics, thereby improving outcomes for patients suffering from these debilitating gastrointestinal disorders.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Cybin is a biopharmaceutical company dedicated to advancing research and development in psychedelic and medicinal mushrooms. It focuses on creating safe and effective therapeutics for mental health issues, with an emphasis on psilocybin-based products. The company is actively launching these products in jurisdictions where they are permitted and is engaged in clinical studies across North America and other regions. Through strategic partnerships with academic and institutional entities, Cybin seeks to develop novel compounds and delivery mechanisms, aiming to provide innovative treatments for various psychiatric and neurological conditions.

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of microRNA-targeted therapies for various diseases. Founded in 2007 and headquartered in San Diego, California, the company focuses on innovative treatments for conditions such as kidney diseases and viral infections. Its lead product candidates include RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for Alport syndrome, and RGLS4326, an anti-miR targeting miR-17, which is undergoing Phase Ib clinical trials for autosomal dominant polycystic kidney disease. Additionally, Regulus is advancing a pipeline of preclinical drug candidates, including RGLS5579 to inhibit miR-10b, as well as programs aimed at treating Hepatitis B virus and Non-Alcoholic Steatohepatitis. The company's work leverages the recent scientific advancements in microRNA research, which play a crucial role in regulating gene expression.

Mind Medicine Inc. is a biopharmaceutical company focused on discovering, developing, and deploying psychedelic-inspired medicines and therapies aimed at addressing addiction and mental health issues. Headquartered in New York, the company is building a diverse drug development pipeline that includes innovative treatments derived from psychedelic substances such as Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative known as 18-MC. Founded in 2010 by JR Rahn, Scott Freeman, Leonard Latchman, and Stephen L. Hurst, MindMed is actively engaged in forming collaborations and conducting clinical trials to further explore the therapeutic potential of these substances in treating brain health disorders.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for post-surgical ocular pain, inflammation, and allergic conjunctivitis, and is also being investigated for dry eye diseases. Additionally, Ocular Therapeutix is developing several other products, including OTX-TP, an intracanalicular travoprost insert for glaucoma, and OTX-TKI, an intravitreal implant for wet age-related macular degeneration, among others. The company has established a strategic collaboration with Regeneron Pharmaceuticals to leverage its hydrogel technology in combination with Regeneron's VEGF-targeting compounds for retinal diseases. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to address unmet needs in ophthalmology through its advanced therapeutic solutions.

LB Pharmaceuticals Inc is a New York-based life sciences company focused on the discovery and development of drugs for central nervous system disorders. Established in 2015, the company is dedicated to commercializing novel and improved versions of well-established CNS treatments that have been successfully utilized abroad but have not been developed or marketed in the United States. LB Pharmaceuticals aims to create intellectual property around these advanced treatments, with its lead asset being LB-102, a patented version of amisulpride, widely recognized for its effectiveness in treating schizophrenia. By employing a pro-drug approach that alters amisulpride's chemical structure, the company seeks to enhance the drug's efficacy and safety, thereby providing improved treatment options for patients who do not respond adequately to existing therapies.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies aimed at transforming the treatment landscape for inflammatory bowel disease (IBD). By leveraging advanced antibody engineering, rational therapeutic combinations, and precision medicine strategies for patient selection, Spyre Therapeutics seeks to create next-generation products that address the chronic inflammation associated with IBD, which includes ulcerative colitis and Crohn's disease. The company aims to enhance existing treatment options, which currently include anti-inflammatory drugs, immunosuppressants, and biologics, thereby improving outcomes for patients suffering from these debilitating gastrointestinal disorders.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and based in South San Francisco, California. The company is dedicated to developing innovative therapeutics to meet unmet medical needs in viral and liver diseases. Its primary focus is on chronic hepatitis B (CHB), with a robust pipeline that includes several drug candidates: ALG-010133, a synthetic oligonucleotide currently in Phase I clinical trials; ALG-000184, a capsid assembly modulator; ALG-020572, another oligonucleotide; and ALG-125097, an siRNA drug candidate. Additionally, Aligos is advancing ALG-055009, a small molecule THR-ß agonist aimed at treating non-alcoholic steatohepatitis (NASH). Aligos aims to leverage its expertise in liver diseases and viral infections to develop targeted antiviral therapies and establish itself as a leader in this therapeutic area.

Tourmaline Bio is a clinical biotechnology company focused on developing transformative medicines aimed at improving the lives of patients suffering from immune diseases. The company is in the late stages of clinical development and is centered on its lead product candidate, TOUR006, a fully human monoclonal antibody designed to selectively target interleukin-6 (IL-6), a significant proinflammatory cytokine implicated in various autoimmune and inflammatory disorders. The IL-6 antibody class has a well-established history, with over two decades of clinical and commercial experience, having successfully treated more than a million patients with diverse autoimmune and inflammatory conditions. Through its innovative research, Tourmaline Bio seeks to address the unmet medical needs of patients affected by life-altering immune diseases.

Mariana Oncology is a biotechnology company focused on developing innovative radiopharmaceuticals aimed at targeting cancer cells with radioactive drugs. The company employs a multidisciplinary approach that includes ligand discovery, radiochemistry, radiobiology, and translational and clinical research in oncology. By building a diverse pipeline of treatments for various solid tumor types, Mariana Oncology seeks to enhance the efficacy of radio medicines in cancer therapy, ultimately aiding medical professionals in their efforts to improve patient outcomes.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Carmot Therapeutics, Inc. is a clinical-stage biotechnology company based in Berkeley, California, with an additional office in San Francisco. Founded in 2008, it focuses on discovering and developing innovative therapies for patients with metabolic diseases, including obesity and diabetes. Utilizing its proprietary Chemotype Evolution technology, Carmot Therapeutics aims to address the underlying causes of these conditions and accelerate the discovery of effective treatments. The company’s portfolio includes several clinical-stage drug candidates, such as CT-388 and CT-996, which are designed as GLP-1 receptor agonists for the treatment of obesity and type 2 diabetes, and CT-868, intended for type 1 diabetes patients who are overweight or obese. Through these efforts, Carmot Therapeutics seeks to create life-changing therapeutics that improve the health outcomes of individuals affected by metabolic diseases.

OnKure Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of innovative cancer therapies. The company specializes in creating less toxic kinase inhibitor drugs and epigenetic therapies, including selective inhibitors of histone deacetylases. Its lead candidate, OKI-179, has demonstrated significant efficacy in preclinical models of hematological and solid tumor cancers, effectively reducing tumor growth both alone and in combination with other targeted therapies. Additionally, OnKure is advancing its HDAC3 selective inhibitor, OKI-422, into preclinical toxicology studies. The company's drug candidates are designed to directly target malignant cells, enhance the effects of small molecule therapies, and optimize the tumor microenvironment for improved checkpoint inhibition, addressing unmet medical needs in cancer treatment.

Zura Bio is a clinical-stage biotechnology company dedicated to developing innovative therapies for immune and inflammatory disorders. It focuses on advancing its pipeline of treatments through phase 2 development programs, including ZB-168 and torudokimab, which target autoimmune illnesses. ZB-168 is an anti-IL7R inhibitor designed to address disorders linked to IL7 and TSLP biological pathways, building on encouraging phase 1b data related to type 1 diabetes. Torudokimab, a human-affinity monoclonal antibody, is in phase 2 clinical development and works by neutralizing IL33. Through these initiatives, Zura Bio aims to create effective therapeutic options for patients suffering from complex immune-related conditions.

TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, antibody-based therapies aimed at enhancing the lives of cancer patients. The company specializes in antibody-drug conjugates and other biologics, focusing on oncologic diseases with significant unmet medical needs. TORL BioTherapeutics employs a strategy that involves target identification and early discovery work, allowing them to selectively advance drug programs through novel licensing agreements. This approach enables their researchers to develop proprietary drugs with unique and optimized profiles, contributing to the advancement of cancer treatment options.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Abivax is a clinical-stage biotechnology company based in France, dedicated to developing innovative therapeutics that leverage the body's natural immune mechanisms to treat patients with autoimmune diseases, viral infections, and cancer. The company's primary focus is on chronic inflammatory diseases, particularly inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Abivax is currently evaluating its leading drug candidate, obefazimod, in Phase 3 clinical trials aimed at addressing moderately to severely active ulcerative colitis. Through its drug development platforms, Abivax strives to deliver novel and effective treatments to patients with significant unmet medical needs in these therapeutic areas.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Tourmaline Bio is a clinical biotechnology company focused on developing transformative medicines aimed at improving the lives of patients suffering from immune diseases. The company is in the late stages of clinical development and is centered on its lead product candidate, TOUR006, a fully human monoclonal antibody designed to selectively target interleukin-6 (IL-6), a significant proinflammatory cytokine implicated in various autoimmune and inflammatory disorders. The IL-6 antibody class has a well-established history, with over two decades of clinical and commercial experience, having successfully treated more than a million patients with diverse autoimmune and inflammatory conditions. Through its innovative research, Tourmaline Bio seeks to address the unmet medical needs of patients affected by life-altering immune diseases.

Apogee Therapeutics is a San Francisco-based biotechnology company founded in 2022, specializing in the development of novel therapies for immunological and inflammatory disorders. The company focuses on creating differentiated biologics to treat conditions such as atopic dermatitis and chronic obstructive pulmonary disease, addressing significant unmet medical needs. Apogee's approach involves advancing antibody programs designed to target established mechanisms of action while utilizing advanced engineering techniques to enhance the therapeutic properties, including extended half-life. The company is actively developing two main programs: APG777 for atopic dermatitis and APG808 for chronic obstructive pulmonary disease.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Immunovant, headquartered in New York, is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with autoimmune diseases. Its primary focus is on developing monoclonal antibodies, notably IMVT-1401, a fully human antibody that targets the neonatal Fc receptor (FcRn). This investigational product is designed for subcutaneous injection and aims to address various IgG-mediated autoimmune conditions. IMVT-1401 is currently in Phase IIa clinical trials for myasthenia gravis and thyroid eye disease, with Phase II trials also initiated for warm autoimmune hemolytic anemia. Additionally, the company is developing batoclimab and IMVT-1402, both targeting FcRn.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

Allakos Inc. is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Redwood City, California. The company focuses on developing antibody-based therapeutics aimed at treating diseases associated with dysregulation of the T-helper type 2 immune response, which plays a crucial role in various allergic and inflammatory conditions. Its lead product, antolimab (AK002), is being investigated for the treatment of eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is developing AK006, an antibody that targets the Siglec-6 receptor on mast cells, designed to activate the receptor's inhibitory function and reduce mast cell activation. Through these innovative therapies, Allakos aims to address the underlying mechanisms of diseases characterized by excessive inflammatory responses.

Abivax is a clinical-stage biotechnology company based in France, dedicated to developing innovative therapeutics that leverage the body's natural immune mechanisms to treat patients with autoimmune diseases, viral infections, and cancer. The company's primary focus is on chronic inflammatory diseases, particularly inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Abivax is currently evaluating its leading drug candidate, obefazimod, in Phase 3 clinical trials aimed at addressing moderately to severely active ulcerative colitis. Through its drug development platforms, Abivax strives to deliver novel and effective treatments to patients with significant unmet medical needs in these therapeutic areas.

Heron Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative treatments to address unmet medical needs. The company utilizes its proprietary Biochronomer drug delivery technology, which enables sustained release of therapeutic agents over days to weeks with a single administration. Heron's product portfolio includes SUSTOL, an extended-release injection for preventing nausea and vomiting associated with chemotherapy, and CINVANTI, an intravenous formulation for similar indications. Additionally, the company is advancing HTX-011, a dual-acting combination of bupivacaine and meloxicam, currently in Phase III clinical trials for pain management, and HTX-034, aimed at postoperative pain relief. Founded in 1983, Heron Therapeutics was previously known as A.P. Pharma, Inc. before rebranding in 2014.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on designing and developing novel oral therapeutics to treat chronic diseases with high unmet need. Utilizing advanced computational and structure-based technology, the company creates life-changing medicines by integrating cutting-edge advancements in computational chemistry and molecular interaction visualization. Its pipeline includes GSBR-1290, an oral glucagon-like-peptide-1 receptor agonist for type-2 diabetes mellitus and obesity, as well as ANPA-0073 and LTSE-2578 targeting pulmonary and cardiovascular diseases respectively. The company's team, with deep experience in complex biological targets and structure-based drug design, aims to deliver efficacious and safe treatments with broad commercial potential.

Carmot Therapeutics, Inc. is a clinical-stage biotechnology company based in Berkeley, California, with an additional office in San Francisco. Founded in 2008, it focuses on discovering and developing innovative therapies for patients with metabolic diseases, including obesity and diabetes. Utilizing its proprietary Chemotype Evolution technology, Carmot Therapeutics aims to address the underlying causes of these conditions and accelerate the discovery of effective treatments. The company’s portfolio includes several clinical-stage drug candidates, such as CT-388 and CT-996, which are designed as GLP-1 receptor agonists for the treatment of obesity and type 2 diabetes, and CT-868, intended for type 1 diabetes patients who are overweight or obese. Through these efforts, Carmot Therapeutics seeks to create life-changing therapeutics that improve the health outcomes of individuals affected by metabolic diseases.

Third Harmonic Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for severe allergies and inflammation. The company is focused on advancing its lead product candidate, THB001, which is a first-in-class, highly selective oral inhibitor of the KIT receptor, a key regulator of mast cell function and survival. Mast cells play a crucial role in mediating inflammation in allergic diseases, making this targeted approach significant for treatment. Additionally, Third Harmonic Bio is developing THB335, another potent and selective oral small-molecule KIT inhibitor aimed at addressing various mast cell-driven inflammatory conditions affecting the skin, airway, and gastrointestinal tract. Through its research and development efforts, Third Harmonic Bio seeks to provide new options for patients suffering from inflammatory diseases.

Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, established in 2013. The company specializes in the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a common complication of CKD, can accelerate kidney deterioration and is associated with serious health risks, including muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, positioning the company to address a significant unmet medical need in CKD management through the innovative approach of binding and removing acid from the gastrointestinal tract.

Obsidian Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing next-generation cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Its innovative approach utilizes pharmacologic operating systems that enable precise control over protein activity within cells. This technology allows for the creation of adoptive cell therapies with novel functionalities, which can be regulated by treating physicians using simple and safe orally active medications. Through these advancements, Obsidian Therapeutics seeks to improve upon existing cell therapies and expand treatment options for a broader patient demographic.

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company focused on developing drug candidates for central nervous system diseases and cancer. The company is advancing its lead drug candidate, ANAVEX 2-73, through various clinical trials, including Phase III for Alzheimer’s disease and Rett syndrome, and Phase II for Parkinson’s disease. Additionally, it is involved in preclinical trials for a range of conditions such as epilepsy, Fragile X syndrome, multiple sclerosis, and tuberous sclerosis complex. Anavex also develops other potential therapies, including ANAVEX 3-71 for frontotemporal dementia and several preclinical candidates targeting conditions like depression, stroke, and cancer. Utilizing its proprietary SIGMACEPTOR™ platform, Anavex aims to innovate in drug discovery through sigma receptor agonists and antagonists. The company is headquartered in New York, New York.

BioTheryX, Inc. is a clinical-stage biopharmaceutical company based in Chappaqua, New York, that specializes in restoring protein homeostasis through innovative small molecule therapies. The company develops Protein Homeostatic Modulators, including a small molecular glue that targets cereblon for protein degradation, with applications in oncology, inflammation, and other diseases. BioTheryX employs its proprietary PRODEGY platform, which utilizes a library of cereblon binders to design targeted protein degraders (TPDs). Among its key products is BTX-A51, an oral multi-kinase inhibitor aimed at treating specific leukemic stem cell targets and preventing the transcription of oncogenic genes. Founded in 2007, BioTheryX aims to address unmet medical needs by leveraging its expertise in targeted protein degradation.

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on advancing stem cell transplantation and related therapies. Founded in 2015, the company aims to enhance the patient experience in transplant medicine by developing innovative treatments that make stem cell transplants safer and more accessible. Its pipeline includes several key candidates, such as C100, C200, and C300 targeted antibody-drug conjugates designed for transplant conditioning; MGTA-145, a stem cell mobilization product; and MGTA-456, an allogeneic stem cell therapy. Additionally, Magenta is exploring E478, a small molecule aimed at expanding gene-modified stem cells, and G100, an antibody-drug conjugate to mitigate acute graft-versus-host disease. The company has established research collaborations with other biotechnology firms to further investigate the potential of its therapies in treating blood cancers, genetic disorders, and autoimmune diseases, ultimately striving to transform stem cell transplantation from a last-resort option into a more viable and effective treatment for patients.

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company headquartered in San Diego, California, dedicated to the discovery, development, and commercialization of innovative therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist currently undergoing Phase I clinical trials aimed at treating acromegaly and neuroendocrine tumors. In addition to paltusotine, Crinetics is developing several other therapeutics, including CRN01941, an oral selective nonpeptide sst2 biased agonist for neuroendocrine tumors, and an oral somatostatin type 5 receptor agonist for congenital hyperinsulinism. The company is also working on an oral adrenocorticotrophic hormone antagonist for conditions such as Cushing’s syndrome and congenital adrenal hyperplasia. Founded in 2008, Crinetics Pharmaceuticals is focused on leveraging its internal discovery efforts to create effective treatments while utilizing hormonal biomarker endpoints to enhance the efficiency and cost-effectiveness of its clinical studies.